The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
ALS patients experience neuroinflammation and rapid neurodegeneration
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The product is used to treat amyotrophic lateral sclerosis
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Subscribe To Our Newsletter & Stay Updated
